Potential value of Gleason score in predicting the...

Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer

Abstract

AIM: This study aimed to identify predictive/prognostic factors in castration-resistant prostate cancer patients treated with cabazitaxel. PATIENTS & METHODS: Patients were enrolled from March 2011 to December 2011 in an international expanded access program. In January 2012, when cabazitaxel became commercially available, a prospective study was initiated at University Federico II of Naples and at Rionero in Vulture Hospital. RESULTS: Forty-seven patients were enrolled in this study. Patients received a median of nine cycles of cabazitaxel. Median progression-free survival was 7.0 months (95% CI: 5.7-8.0). Seventeen patients were still alive at the time of the analysis, with a median overall survival of 14 months (95% CI: 11-16). At multivariate analysis, a higher Gleason score (≥ 8) appeared to be associated with prolonged progression-free survival (hazard ratio: 0.36; 95% CI: 0.18-0.72); however, the higher Gleason score showed no statistical impact on overall survival. CONCLUSION: We hypothesize that the Gleason score has the potential to be incorporated in the clinical decision-making process for definition of treatment strategy in docetaxel-pretreated castration-resistant prostate cancer patients. We encourage further experimentation in this setting.

Authors

Buonerba C; Pond GR; Sonpavde G; Federico P; Rescigno P; Puglia L; Bosso D; Virtuoso A; Policastro T; Izzo M

Journal

Future Oncology, Vol. 9, No. 6, pp. 889–897

Publisher

Taylor & Francis

Publication Date

June 30, 2013

DOI

10.2217/fon.13.39

ISSN

1479-6694

Associated Experts

Gregory Pond

Professor, Faculty of Health Sciences

Visit profile

Labels